268 related articles for article (PubMed ID: 32167970)
21. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
[TBL] [Abstract][Full Text] [Related]
22. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
23. Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.
Taylor N; Kremser I; Auer S; Hoermann G; Greil R; Haschke-Becher E; Esterbauer H; Kenner L; Oberkofler H
J Acquir Immune Defic Syndr; 2017 May; 75(1):e13-e20. PubMed ID: 27798431
[TBL] [Abstract][Full Text] [Related]
24. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
[TBL] [Abstract][Full Text] [Related]
25. Suppression of TRPM2 reduces renal fibrosis and inflammation through blocking TGF-β1-regulated JNK activation.
Wang Y; Chen L; Wang K; Da Y; Zhou M; Yan H; Zheng D; Zhong S; Cai S; Zhu H; Li Y
Biomed Pharmacother; 2019 Dec; 120():109556. PubMed ID: 31655312
[TBL] [Abstract][Full Text] [Related]
26. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
Tasias M; Aldeguer JL
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
[TBL] [Abstract][Full Text] [Related]
27. Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir.
Santiago F; Oguma J; Brown AM; Laurence J
Biochem Biophys Res Commun; 2012 Jan; 417(1):223-30. PubMed ID: 22142846
[TBL] [Abstract][Full Text] [Related]
28. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
[TBL] [Abstract][Full Text] [Related]
29. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
30. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of Nrf2/HO-1 and inhibition of TGF-β1/Smad2/3 signaling axis by daphnetin alleviates transverse aortic constriction-induced cardiac remodeling in mice.
Syed AM; Kundu S; Ram C; Kulhari U; Kumar A; Mugale MN; Mohapatra P; Murty US; Sahu BD
Free Radic Biol Med; 2022 Jun; 186():17-30. PubMed ID: 35513128
[TBL] [Abstract][Full Text] [Related]
32. Dose-finding study of a once-daily indinavir/ritonavir regimen.
Hugen PW; Burger DM; ter Hofstede HJ; Koopmans PP; Stek M; Hekster YA; Reiss P; Lange JM
J Acquir Immune Defic Syndr; 2000 Nov; 25(3):236-45. PubMed ID: 11115954
[TBL] [Abstract][Full Text] [Related]
33. Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.
Bradshaw EL; Li XA; Guerin T; Everson WV; Wilson ME; Bruce-Keller AJ; Greenberg RN; Guo L; Ross SA; Smart EJ
Am J Physiol Cell Physiol; 2006 Dec; 291(6):C1271-8. PubMed ID: 16822947
[TBL] [Abstract][Full Text] [Related]
34. Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury.
Ghafoory S; Varshney R; Robison T; Kouzbari K; Woolington S; Murphy B; Xia L; Ahamed J
Blood Adv; 2018 Mar; 2(5):470-480. PubMed ID: 29490978
[TBL] [Abstract][Full Text] [Related]
35. Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-β1 regulator and activating the Nrf2 signaling pathway.
Zhang H; Qi S; Song Y; Ling C
Life Sci; 2020 Sep; 256():117966. PubMed ID: 32535079
[TBL] [Abstract][Full Text] [Related]
36. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
37. Delayed treatment with oleanolic acid attenuates tubulointerstitial fibrosis in chronic cyclosporine nephropathy through Nrf2/HO-1 signaling.
Hong YA; Lim JH; Kim MY; Kim EN; Koh ES; Shin SJ; Choi BS; Park CW; Chang YS; Chung S
J Transl Med; 2014 Feb; 12():50. PubMed ID: 24559268
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).
Hwang C; Schürmann D; Sobotha C; Boffito M; Sevinsky H; Ray N; Ravindran P; Xiao H; Keicher C; Hüser A; Krystal M; Dicker IB; Grasela D; Lataillade M
Clin Infect Dis; 2017 Aug; 65(3):442-452. PubMed ID: 28369211
[TBL] [Abstract][Full Text] [Related]
39. Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Bonjoch A; Puig J; Pérez-Alvarez N; Juega J; Echeverría P; Clotet B; Romero R; Bonet J; Negredo E
Medicine (Baltimore); 2016 Aug; 95(32):e4507. PubMed ID: 27512868
[TBL] [Abstract][Full Text] [Related]
40. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
